Audentes to develop vectorized antisense therapies with Nationwide

Audentes partnered with Nationwide Children's Hospital to develop antisense oligonucleotides delivered with the biotech's adeno-associated viral (AAV) vectors to treat muscular dystrophies.

Audentes Therapeutics Inc. (NASDAQ:BOLD) Chairman and CEO Matt Patterson told BioCentury the decision to move into antisense therapies came as the company was looking to leverage its AAV manufacturing capabilities to expand its neuromuscular pipeline. Patterson added that the company saw an opportunity to use AAV vectors, which have "evolved to be extremely efficient in penetrating tissues," to develop vectorized antisense therapies that overcome the biodistribution limitations of antisense oligonucleotide-based therapies...